Patents by Inventor Naama MAIMON

Naama MAIMON has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHOD FOR DETERMINING SUITABILITY TO ANTI-TNF ALPHA THERAPY
    Publication number: 20240117438
    Abstract: The present invention is directed to a kit and a method for determining the suitability of a subject to a treatment using a tumor necrosis factor alpha (TNF?). Further provided is a method for treating the subject determined to be suitable for a treatment using a TNF? inhibitor.
    Type: Application
    Filed: December 13, 2023
    Publication date: April 11, 2024
    Inventors: Shai SHEN-ORR, Yehuda CHOWERS, Shiran GERASSY-VAINBERG, Alexandra BLATT, Elina STAROVETSKY, Renaud Gilles GAUJOUX, Naama MAIMON
  • Infiltrating immune cell proportions predict anti-TNF response in colon biopsies
    Patent number: 11262358
    Abstract: Provided are methods of predicting responsiveness of a subject having an inflammatory bowel disease (IBD) to a tumor necrosis factor (TNF)-alpha inhibitor, by analyzing a frequency of at least one subpopulation of immune cells in a tissue biopsy of the subject. Also provided are methods of selecting a treatment for a subject and kits for determining responsiveness of the subject to treatment with a TNF-alpha inhibitor.
    Type: Grant
    Filed: April 6, 2017
    Date of Patent: March 1, 2022
    Assignees: Technion Research & Development Foundation Limited, The Board of Trustees of the Leland Stanford Junior University
    Inventors: Shai S. Shen-Orr, Elina Starovetsky, Naama Maimon, Purvesh Khatri, Renaud Gaujoux, Francesco Vallania
  • INFILTRATING IMMUNE CELL PROPORTIONS PREDICT ANTI-TNF RESPONSE IN COLON BIOPSIES
    Publication number: 20190094223
    Abstract: Provided are methods of predicting responsiveness of a subject having an inflammatory bowel disease (IBD) to a tumor necrosis factor (TNF)-alpha inhibitor, by analyzing a frequency of at least one subpopulation of immune cells in a tissue biopsy of the subject. Also provided are methods of selecting a treatment for a subject and kits for determining responsiveness of the subject to treatment with a TNF-alpha inhibitor.
    Type: Application
    Filed: April 6, 2017
    Publication date: March 28, 2019
    Applicants: Technion Research & Development Foundation Limited, The Board of Trustees of the Leland Stanford Junior University
    Inventors: Shai S. SHEN-ORR, Elina STAROVETSKY, Naama MAIMON, Purvesh KHATRI, Renaud GAUJOUX, Francesco VALLANIA